Data / Form D filings / Forte Biosciences, Inc.
Forte Biosciences, Inc.: Form D filings
Forte Biosciences, Inc., a biotechnology company in Dallas, TX, filed 21 Form D notices with the SEC between 2009 and 2023. The latest, on August 9, 2023, reports $25 million sold of a $25 million offering to 27 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3060 PEGASUS PARK DRIVE, BUILDING 6, Dallas, TX, 75247
- Phone
- (310) 618-6994
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1419041
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 9, 2023 | New notice | $25,009,981 | $25,009,981 | 27 | Jul 31, 2023 | sec.gov | |
| Mar 13, 2017 | Amendment | $13,000,000 | $10,895,750 | $2,104,250 | 107 | Nov 21, 2016 | sec.gov |
| Dec 6, 2016 | New notice | $10,000,000 | $2,735,750 | $7,264,250 | 17 | Nov 21, 2016 | sec.gov |
| Oct 22, 2015 | Amendment | $50,400,000 | $46,200,326 | $4,199,674 | 250 | May 20, 2013 | sec.gov |
| Aug 10, 2015 | Amendment | $39,900,000 | $28,804,537 | $11,095,463 | 156 | May 20, 2013 | sec.gov |
| Jul 3, 2014 | Amendment | $15,750,000 | $8,509,599 | $7,240,401 | 77 | May 20, 2013 | sec.gov |
| Jun 10, 2013 | New notice | $5,250,000 | $210,000 | $5,040,000 | 3 | May 20, 2013 | sec.gov |
| Dec 5, 2012 | Amendment | $15,000,000 | $9,055,340 | $5,944,660 | 32 | Feb 21, 2012 | sec.gov |
| Mar 7, 2012 | New notice | $5,000,000 | $1,150,000 | $3,850,000 | 4 | Feb 21, 2012 | sec.gov |
| Nov 8, 2011 | Amendment | $28,160,000 | $15,310,930 | $12,849,070 | 88 | Dec 20, 2010 | sec.gov |
| Feb 16, 2011 | Amendment | $9,900,000 | $3,720,226 | $6,179,774 | 33 | Dec 20, 2010 | sec.gov |
| Jan 4, 2011 | New notice | $3,300,000 | $1,058,002 | $2,241,998 | 10 | Dec 20, 2010 | sec.gov |
| Oct 5, 2010 | Amendment | $12,000,000 | $5,269,000 | $6,731,000 | 43 | Jun 30, 2010 | sec.gov |
| Jul 23, 2010 | New notice | $6,000,000 | $2,135,000 | $3,865,000 | 24 | Jun 30, 2010 | sec.gov |
| Mar 5, 2010 | New notice | $8,000,000 | $7,776,750 | $223,250 | 75 | Feb 2, 2010 | sec.gov |
| Feb 26, 2010 | New notice | $3,000,001 | $3,000,001 | 2 | Jan 27, 2010 | sec.gov | |
| Nov 23, 2009 | Amendment | $10,000,000 | $9,116,162 | $883,838 | 100 | Jun 12, 2009 | sec.gov |
| Jun 18, 2009 | New notice | $5,000,000 | $1,000,000 | $4,000,000 | 1 | Jun 12, 2009 | sec.gov |
| Jun 2, 2009 | Amendment | $11,250,000 | $10,846,000 | $404,000 | 99 | Sep 5, 2008 | sec.gov |
| May 15, 2009 | Amendment | $11,250,000 | $10,846,000 | $404,000 | 99 | Sep 5, 2008 | sec.gov |
| Apr 10, 2009 | Amendment | $9,000,000 | $7,095,750 | $1,904,250 | 71 | Sep 5, 2008 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Antony Riley | Executive Officer | |
| Stephen Doberstein | Director | |
| Scott Brun | Director | |
| Lawrence Eichenfield | Director | |
| Hubert Chen | Executive Officer | |
| Steven Kornfeld | Director | |
| David Gryska | Director | |
| Barbara Fink | Director | |
| Donald Williams | Director | |
| Paul Wagner | Executive Officer, Director |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of Aug 7, 2023 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Forte Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.